BDSX vs CAI
BDSX: Biodesix develops precision diagnostic tests powered by molecular and AI analysis to guide oncology treatment decisions for clinicians, payers, and biopharmaceutical companies. CAI: Caris Life Sciences delivers precision oncology and molecular profiling solutions that help biopharma companies and physicians make treatment decisions through comprehensive tumor analysis.
Side-by-side fundamentals
| Metric | BDSX | CAI | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $22.22 | $16.09 | |
| Market cap as of 2026-07-31 | $221M | $4.4B | |
| P/E as of 2026-07-31 | n/a | 141.51 | |
| PEG as of 2026-07-31 | n/a | -0.97 | |
| Net margin as of 2026-07-31 | -33.3% | +3.8% | CAI higher |
| Gross margin as of 2026-07-31 | +82.1% | +68.7% | BDSX higher |
| Operating margin as of 2026-07-31 | -25.9% | +9.8% | CAI higher |
| ROE as of 2026-07-31 | -375.1% | +6.5% | CAI higher |
| ROA as of 2026-07-31 | -35.6% | +3.2% | CAI higher |
| Debt / equity as of 2026-07-31 | 5.09 | 0.64 | CAI lower |
| Revenue growth (YoY) as of 2026-07-31 | +29.1% | +78.8% | CAI higher |
| Revenue CAGR (3y) SEC XBRL | +32.3% | +62.9% | CAI higher |
| Beta as of 2026-07-31 | 0.59 | 1.33 | |
| 1-year return as of 2026-07-27 close | +149.1% | -45.5% | BDSX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.